RET and neoplasm: In our case pralsetinib exhibited a significant response in a patient with NSCLC and an RET fusion and transformed the unresectable tumor into a resectable tumor; however, 26% of the tumor cells were still alive after pralsetinib neoadjuvant treatment, indicating the necessity of complete resection.